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be the registration of generic of paclitaxel in Poland. While the
changes in the cost structure in CC group could been produced
by including the costs of additional medication into the cost of
hospitalization.
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OBJECTIVE: The introduction of DRGs in 2004 requires
German hospitals to gain cost transparency and optimize budget
allocation. We compared two different chemo regimens (4× EC
followed by 4× docetaxel q21, EC→DOC vs. 6× CMF, day 1 +
8, q28) for patients with node positive primary breast cancer
regarding costs of resource consumption. METHODS: Data
were obtained piggyback during 2/2000–5/2002 on the German
prospective, longitudinal, randomized, multicenter Phase III
EC→DOC trial closed in 8/2005. Evaluation of diagnostic effort
was based on a comprehensive monocentric retrospective chart
review. To allocate costs to health care resources German tariffs
in €2005 and hospital databases were used. Costs were presented
from hospital provider perspective. Sensitivity and scenario
analyses were conducted. RESULTS: Altogether a cohort of 110
patients who received 1047 cycle days at 38 study centers was
analyzed. The average patient age was 52.4 years. Mean direct
costs for EC→DOC group totaled €8.459 per patient (N = 54).
Costs for cytostatics accounted for the largest portion with
€5.673 (67%), staff costs for drug application and pharmacy ser-
vices including transport averaged out €1.357 (16%), average
hospital basic costs were €414 (4.9%) and €376 (4.4%) for diag-
nostic effort and port or catheter implantation. Hospitals spent
€354 (4.2%) on supportive drugs, administration devices and
infusion bags and €313 (3.7%) on rehospitalisation (8 times in
7 patients). In contrast to rather expensive EC→DOC, CMF was
€3.486 less costly (−41.2%), but savings for CMF acquisition
cost with −€5.598 were partially compensated by higher costs
for medical and diagnostic effort or hospital hotel services.
Results were most sensitive to docetaxel acquisition cost and the
percentage of patients with incomplete chemotherapy. CON-
CLUSION: Our results will enable German hospitals to develop
strategies of ﬁnancing a consequential 70% budget increase
caused by introducing sequential docetaxel in adjuvant
chemotherapy of breast cancer.
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OBJECTIVES: Erlotinib, a new second-line therapy option in
patients with NSCLC, leads to similar overall survival improve-
ment but has a more favourable adverse events (AEs) proﬁle
compared to docetaxel and pemetrexed. The objective of the
present study was to compare the costs per patient treated with
erlotinib with those for docetaxel and pemetrexed for Germany
taking the management of AEs into account. METHODS: Direct
quarterly medical care costs per patient without considering AEs
(“base costs”) and those including costs of treating AEs (“total
costs”) were compared for the assessed therapy regimes. For cal-
culating base costs, costs for physician visits, drugs and drug
administration were considered. Total costs also included mean
costs for treating drug-related AEs grade 3/4 according to the US
National Cancer Institute classiﬁcation per patient under the
respective therapy. Resource utilisation data were obtained from
two multinational, randomized phase III trials. Further required
data was estimated based on national guidelines and prescribing
information for the drugs considered. The analysis was con-
ducted from the German payers’ perspective. Cost data were
derived from published sources for the year 2005. Due to the
short time horizon of one quarter the outcomes were not dis-
counted. One-way sensitivity analysis on cost data was per-
formed. RESULTS: Quarterly base costs per patient for erlotinib
are comparable to those for docetaxel (€8172 vs. €8055) and
about €7700 lower than those for pemetrexed (€8172 vs.
€15,870). Total quarterly costs per patient including costs of
treating AEs for erlotinib are about €1700 lower than for doc-
etaxel and about €8300 lower than for pemetrexed (€8374 vs.
€10,086 and €16,715, respectively). Sensitivity analyses con-
ﬁrmed the robustness of the results. CONCLUSIONS: Due to
the favourable tolerability proﬁle, the treatment with erlotinib is
cost-saving for the German health care system compared to doc-
etaxel and pemetrexed.
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Even if the clinical efﬁcacy of recombinant human erythropoi-
etin on chemotherapy-induced anemia was demonstrated, most
economic studies have given unfavorable results, whatever the
design and the outcome considered. OBJECTIVE: To calculate
the incremental cost-effectiveness ratio (ICER) of darbepoetin
alfa (Aranesp) as compared to standard palliative care in a
cohort of patients treated by chemotherapy for lung cancer in
clinical practice. METHOD: A Markov model was constructed
to evaluate the cost effectiveness ratio of one weekly injection
darbepoetin (Aranesp) compared with palliative standard care
(red blood transfusion if hg <8 g/dl) in the correction of
chemotherapy-induced anemia. Baseline probabilities and con-
sumed resources were calculated on the basis of a two-year ret-
rospective study, comparing two cohorts of patients treated by
chemotherapy who received (n = 94) or did not receive (n = 89)
Aranesp. The incremental cost-effectiveness ratio (ICER) was
calculated as the difference in direct costs from a health care per-
spective (transfusion requirement and anemia management
costs) divided by the difference in effect (changes in haemoglo-
bin levels). Sensitivity analysis was used to test uncertain data.
RESULTS: The use of Aranesp signiﬁcantly reduced the propor-
tion of patients needing transfusions (from 33.6% to 19.1%, 
p < 0.05) and the number of red cell units used by transfusion
(from 2.97 ± 1.47 to 2.11 ± 0.47, p < 0.01). Markov modeling
showed that the Aranesp strategy signiﬁcantly increased the
mean Hb level (13 ± 0.5 vs 11.9 ± 1 g/dl, p < 0.001), at the price
of an increase in the main cost (respectively 1732 ± 897 and 996
± 643€; p < 0.01). The incremental cost-effectiveness ratio was
estimated to be 202€ per haemoglobin gram gained. Sensitivity
analysis showed that the Aranesp strategy remained dominant in
most situations. CONCLUSION: Routine use of Aranesp
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appears to be cost-effective in patients receiving chemotherapy
for lung cancer.
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TREATMENT OF RELAPSED NON-SMALL CELL LUNG
CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH
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OBJECTIVE: Pharmacoeconomic assessment of erlotinib
(Tarceva) vs best supportive care (BSC) for the treatment of
relapsed NSCLC conducted as part of the Canadian reimburse-
ment submission. METHODS: Analyses were conducted from
the perspective of the Canadian public health care system, and
included cost-effectiveness (CE) of erlotinib vs BSC. The decision
analytic model included three health states (progression-free,
progression and death) with a time horizon of 24–36 months.
The model is a straight forward calculation of the area under the
curve for time spent in the progression-free and progression
health states. The model structure follows the disease pathway
for NSCLC patients and the outcomes captured in the clinical
trials. Cost components included drug acquisition, physician
visits, hospitalizations, laboratory and diagnostic tests/proce-
dures. Deterministic sensitivity analyses were performed.
RESULTS: Incremental CE ratio at 3 years discounted at 5% is
Can $71,018/Life Year Gained vs BSC. During the reimburse-
ment submission process the Common Drug Review (CDR), and
subsequently the Ontario provincial Ministry of Health (MoH)
questioned whether erlotinib should be restricted to certain sub-
groups (i.e. adenocarcinoma histology or HER1/EGFR-positive
groups). However, the pivotal BR.21 erlotinib trial showed an
overall survival beneﬁt in an unselected patient population (56%
HER1/EGFR status unknown). As all BR.21 molecular subgroup
analyses were exploratory and underpowered, tests of interac-
tion did not identify a molecular subgroup with a better survival
when treated with erlotinib that was statistically signiﬁcant. In
particular HER1/EGFR protein expression was not found to
impact on survival in the BR.21 trial. Based on these data, the
CDR and MoH in Ontario subsequently conﬁrmed subgroup-
speciﬁc CE analyses were not required. CONCLUSIONS:
Erlotinib received positive recommendations from the CDR.
Ontario, British Columbia, Quebec, Nova Scotia and New-
foundland are provinces currently reimbursing erlotinib from
their provincial drug plans.
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OBJECTIVES: The aim of the study was to evaluate the cost-
effectiveness of erlotinib compared to docetaxel and pemetrexed
after failure of previous treatment for stage IIIB/IV NSCLC in
Poland. METHODS: Markov health-state model was used to
estimate the direct medical costs and outcomes (overall survival
and QALY) of treating NSCLC in the Polish setting. This model
incorporates clinical data from published pivotal trials and local
data of health care resource utilisation and unit cost. The per-
spective of health care payers and time horizon of 3 years was
considered. Probabilistic sensitivity analysis was used to address
uncertainty. RESULTS: There were no differences between
treatments with respect to overall survival (0.83 year) and the
number of QALY—0.26 (erlotinib and pemetrexed) and 0.24
(docetaxel). The expected average costs/patient treated with
erlotinib, docetaxel and pemetrexed were: 51,743, 78,039,
92,385 PLN (1 EURO = 3.8 PLN in 2006). Hence erlotinib dom-
inates both docetaxel and pemetrexed (at least equal efﬁcacy and
lower cost). The average cost saving associated with erlotinib
treatment vs. docetaxel and pemetrexed was 26,295 and 40,642
PLN/patient, respectively. Probabilistic sensitivity analysis con-
ﬁrmed results of the deterministic analysis. In a 100% simula-
tion erlotinib remained a dominant treatment strategy in
comparison to docetaxel and pemetrexed. CONCLUSIONS:
Given the results of the analysis erlotinib as 2nd/3rd line agent
in the treatment of patients with advanced NSCLC may be rec-
ommended as ﬁrst-choice treatment because of its cost-saving
potential in comparison to docetaxel and pemetrexed.
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OBJECTIVES: The oral ﬂuoropyrimidine capecitabine is as
effective but better tolerated than i.v. 5-FU/LV as ﬁrst-line treat-
ment in patients with metastatic colorectal cancer. Costs associ-
ated with the administration route could vary widely according
to national rules and medical practice. We compared costs 
and outcomes of capecitabine, Mayo Clinic and de Gramont 
regimens as adjuvant treatment for stage III colon cancer.
METHODS: We assessed the cost-effectiveness of the three reg-
imens using the French third-party payer perspective, time
horizon and efﬁcacy/safety data (adjusted for indirect compar-
isons) from two published clinical trials [Twelves et al. N Engl J
Med 2005; Andre et al. J Clin Oncol 2003]. Medical resource
use and related-cost of chemotherapy and side-effect treatment
were estimated from the clinical trials and expert opinion. Only
grade 3/4 adverse events were considered when comparing
capecitabine to the de Gramont regimen. We applied French
standard costs to resources consumed and evaluated cost-
effectiveness using relapse-free survival as an efﬁcacy indicator.
One-way sensitivity analyses were performed varying the cost
estimates for each treatment. RESULTS: Capecitabine-treated
patients had a mean life duration increase without treatment
failure of 1.3 months vs. Mayo (35 months vs. 33.7 months). De
Gramont was considered as effective as Mayo. In the base-case
analysis, capecitabine is less costly than the Mayo Clinic
(€3961.04 vs. €10,985.66) and de Gramont (€3697.05 vs.
€7266.06) regimens. Capecitabine appeared to be dominant,
more effective and less costly than either of the 5-FU regimens.
In the sensitivity analyses, capecitabine remained dominant
except for the minimum costs scenario vs. de Gramont. In this
case, the cost-effectiveness ratio was estimated at €4511.36 per
year without relapse. CONCLUSIONS: As adjuvant treatment
for colon cancer, capecitabine decreases medical resources con-
sumed, mainly in hospitals. Its approval in this setting is expected
to bring cost savings and better outcomes.
